Skip to content

Kyoritsu Pharmaceutical Co., Ltd. Kyoritsu Pharmaceutical Co., Ltd. signed a joint research agreement with MabGenesis Co., Ltd. on a novel monoclonal antibody drug for dogs

Kyoritsu Pharmaceutical Co., Ltd.
Kyoritsu Pharmaceutical Co., Ltd. signs a joint research agreement with MabGenesis Co., Ltd. on novel monoclonal antibody drugs for dogs ~ Realizing the creation of innovative veterinary antibody drugs ~
Kyoritsu Pharmaceutical Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo; President and CEO: Takaaki Takai; hereinafter “the Company”) and MabGenesis Co., Ltd. (Headquarters: Yokohama City, Kanagawa; Representative Director: Katsuhiro Shinjo; hereinafter “MabGenesis”) signed a joint research agreement on a novel monoclonal antibody drug for dogs. Based on this agreement, the two companies will aim to create innovative antibody drugs using their proprietary platform technology for antibody creation.
[Image:×678.jpg] [Background of conclusion]
Our company’s mission is to “create a path for animals and humans”, and by introducing innovative technology, we contribute to the health and longevity of dogs and cats, and new technology to provide owners with peace of mind and a rich life. We have been searching for partner companies that own Meanwhile, MabGenesis was looking for a partner who could extend its antibody drug technology to the veterinary drug industry.
This time, we have agreed on the same direction and concluded a joint development agreement for a new monoclonal antibody drug for dogs. [Comment from Makoto Hagiwara, Executive Vice President of Kyoritsu Pharmaceutical Co., Ltd.]
We have focused on antibody drugs, which are one of the better treatments for pets and owners, and have been investigating ways to apply innovative antibody drug technology developed in the human domain to dogs and cats. This time, we will jointly develop antibody drugs for dogs using MabGenesis’ proprietary technology. We would like to work to provide good veterinary medicines not only to Japan but also to the world.
[Comment from Katsuhiro Shinjo, CEO of MabGenesis Inc.]
Innovative veterinary antibody drugs have been created by MabGenesis’ two core technologies, the canine MOURA library and antibody acquisition technology IMPACT, and Kyoritsu Pharmaceutical Co., Ltd.’s high development capabilities and leadership in the veterinary drug industry. We believe that we can deliver safe and effective
therapeutic drugs to animals in need of treatment around the world. [About Kyoritsu Pharmaceutical Co., Ltd.]
Founded in 1955. As a leading company in animal medicine, we develop, manufacture, sell, and import/export pharmaceuticals for dogs and cats, as well as pharmaceuticals for livestock and aquatic animals. Name: Kyoritsu Pharmaceutical Co., Ltd.
Representative: Takaaki Takai, President and Representative Director Company Established: May 1955
Capital: 55 million yen
Number of employees: 699 (as of the end of May 2022)
Business description: Development, manufacturing, sales, import and export of veterinary drugs, etc.
[About MabGenesis Co., Ltd.]
MabGenesis Co., Ltd. is a start-up biopharmaceutical company that provides first-in-class and best-in-class therapeutic monoclonal antibody drugs in the human and animal fields by commercializing antibody research by domestic academia for over 30 years. is. We have the world’s highest quality antibody library (MOURA library) with high functionality and comprehensiveness and highly efficient monoclonal antibody isolation technology (IMPACT), and provide high quality monoclonal antibodies that are difficult to obtain with conventional technology. will provide the pharmaceutical industry with expanded research and development opportunities for new drugs. MabGenesis Co., Ltd. provides innovative antibody drugs based on its proprietary antibody technology to provide new treatments and symptom relief to people suffering from diseases and their companion animals,
contributing to the improvement of their quality of life.
Name: MabGenesis Inc.
Representative: Katsuhiro Shinjo, Representative Director
Company Established: June 2019
Capital: 100 million yen
Number of employees: 10 (as of the end of March 2023)
Business: Research and development of pharmaceuticals
Details about this release:

Copyright (c) PR TIMES Corporation.